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1. Introduction 
Patients with acute leukemia (AL) and hematologic stem cell transplant (HCT) recipients are 
at increased risk for the development of invasive fungal infections (IFI) due to prolonged 
neutropenia and severe immunosupression. The incidence of IFI in these patients has 
increased in recent years [1], which likely reflects changes in clinical practice including 
escalation of treatment intensity; more frequent use of unrelated, mismatched or alternative 
donors as stem cell source; rising number of multiple transplantations; and more frequent 
use of T-cell depleted grafts [2-3]. IFI are associated with high morbidity and mortality in 
the patients with AL and represent a leading cause of infectious mortality in allogeneic HCT 
(allo-HCT) recipients. Therefore, effective preventive strategies, accurate diagnostic 
techniques and optimal treatment approaches are required for an optimal management of 
high risk patients with AL and HCT recipients.  
2. Clinical syndromes 
Clinical symptoms of IFI are often non-specific, therefore a high index of suspicion in high 
risk patients is necessary for timely diagnosis and prompt treatment. Diagnosis of the IFI 
could be challenging, particularly in severely immunocompromised patients as a result of 
blunted inflammatory response due to profound neutropenia and altered T-cell function; 
hence, in such patients clinical and radiologic findings may be very subtle. In the case of 
clinical suspicion of IFI aggressive pursuit of a specific microbiologic diagnosis with early 
recognition and prompt initiation of antifungal therapy are the key components of 
optimizing treatment outcomes. The most common clinical signs are the symptoms of local 
or generalized inflammatory response, primarily persistent fever despite the use of broad 
spectrum antibiotics. Other symptoms significantly depend upon the involved anatomic site 
and causative pathogen.  For example, for mold pathogens, lungs and less commonly 
sinuses are involved; accordingly, the most common symptomatology include dyspnea, 
cough, atypical chest pain, hemoptysis, rash, facial pain, nasal congestion and visual 
symptoms such as periorbital pain, blurred vision and proptosis.  
Among numerous potential pathogens Candida and Aspergillus spp. are the major causative 
fungi leading to life-threatening infectious complications in AL and HCT recipients [4].  
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Invasive Candidasis 
Candida fungemia and invasive Candidasis (IC) often occur during breakdown of mucosal 
barriers because Candida spp. are ubiquitous colonizers of mucosal surfaces [5-6]. Skin was 
previously considered as major source for dissemination of Candida spp., however as it was 
recently demonstrated endogenous Candida spp. could frequently disseminate from a 
patient’s gastrointestinal tract [6]. IC occurs more frequently in patients with GVHD and is 
often associated with the presence of indwelling venous catheters, particularly if they are 
used for the administration of parental nutritional supplementation.  
The most common manifestation of IC is persistent and unexplained fever. In contrast to 
other fungal pathogens, Candida spp. are often identified in the blood by fungal blood 
cultures, but 50% of patients with autopsy-proven IC had no positive blood cultures isolated 
prior to death [7]. Hematogenous dissemination may lead to endophthalmitis, which is 
often associated with visual changes and pain [8]. The lesions of endophthalmitis are due to 
the inflammatory response to the Candida organisms, and thus cannot be seen in 
neutropenia; it most commonly occurs after neutrophil engraftment and frequently is 
associated with only subtle retinal lesions, which can be detected by indirect 
ophthalmoscopy. During hematogenous dissemination Candida spp. can invade the skin,  
joint, muscles and renal tubules, which clinically present as maculopapular skin lesions with 
a tendency to ulcerate, polyarthralgias, polymyalgias and azotemia [9].  Right upper 
abdominal discomfort, elevated transaminases, particularly alkaline phosphatase in the 
persistently febrile patents shortly after neutrophil recovery may indicate the presence of 
hepatosplenic candidiasis [10].  Disseminated Candida can cause central nervous system 
(CNS) syndromes, including meningitis and encephalitis. In HCT recipients who developed 
brain abscesses, Candida spp. accounted for 33% of all cases [11]. Very rarely Candida spp. can 
cause fungal endocarditis, which is the most serious manifestation of IC with symptoms 
similar to those of bacterial endocarditis. 
Mold infections  
Despite being ubiquitous, molds are unable to effectively invade tissues in 
immunocompetent individuals; thus, invasive mold infections (IMI) such as Aspergillosis, 
Zygomycosis, and Fusariosis almost exclusively develop in high-risk patients with 
prolonged neutropenia or in severely immunosuppressed patients [12-13].  Nosocomial IMI 
among patients with AL or HCT recipients  primarily develop as a result of spore 
transmission via inhalation or direct contact [14]. Opportunistic molds, particularly 
Aspergillus and Fusarium spp. can possibly disseminate by a contaminated water, therefore, 
water might be a potential source of IMI in the treatment facilities [15].  Aspergillus spp. 
account for the majority of mold fungal infections, primarily mold pneumonias. Zygomycetes 
are indentified in 10% to 20% of mold pneumonias, Scedosporium spp., Fusarium spp., and 
other molds are responsible for a very small percent of cases [16].   
In the case of invasive Aspergillosis (IA), when infection spreads beyond the respiratory 
tract, patients often develop signs of systemic inflammation and multiorgan failure. In such 
cases, hematogenous dissemination can lead to involvement of the eye, sinuses and 
abdominal organs; however Aspergillus spp. may involve virtually any organ including CNS.  
When involvement of the sinuses occurs, IA often clinically resembles Zygomycosis 
(mucormycosis) of the sinuses. Profoundly immunocompromized patients can occasionally 
develop gastrointestinal IA from swallowed organisms that subsequently invade the gut 
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mucosa, which can present with gastrointestinal bleeding or nonspecific signs of an acute 
abdomen and fever and might be confused with GVHD in allo-HCT recipients or 
neutropenic eneterocolitis in severely neutropenic patients [17-18].   A very serious 
complications occur when fungal invasion directly spreads to central nervous system 
involving various anatomic structures of the brain [19] or to ethmoid sinus with a farther 
advance to cavernous sinus [20]. Hematogenous dissemination to the brain can present as a 
clinical presentation of a cerebral infarction.  In HCT recipients with brain abscesses  
Aspergillus spp. were causative pathogens in 58% of cases and in the majority of cases brain 
abscess in these patients were associated with concomitant pulmonary disease [11]. 
Endocarditits is another serious complication of IA and primarily happens in patients with 
prosthetic heart valves or prolonged fungemia due to fungal colonolization of the central 
venous catheters [21]. Symptoms are similar to those of bacterial endocarditis: persistent 
fever and thromboembolic complication due to septic emboli. Blood cultures are usually 
negative, in contrast to classical bacterial endocarditis and diagnosis is usually made by 
demonstration of hyphae in the embolus with a subsequent culture of the organism. 
Prognosis of these patients is very poor despite an intensive medical and surgical treatment 
with a mortality approaching 100% [22]. Endophthalmitis and cutaneous septic lesions by 
Aspergillus spp. are similar in appearance to those caused by disseminated Candidasis.   
Zygomycetes typically enter through the sinuses, lung parenchyma, skin, and gastrointestinal 
tract with a tendency to disseminate in immunocompromised individuals and clinically 
resemble IA.  A distinctive feature of Zygomycetes is their propensity to invade blood vessels 
and cause thrombosis leading to subsequent necrosis of involved tissues.  
Paronychia is often caused by bacteria or yeasts; however, in severely immunocompromised 
recipients it can be caused by Fusarium spp. or other molds and lead to life-threatening IFI 
[16].   
2. Epidemiology 
Knowledge of the epidemiology of IFI is crucial for development of optimal prophylactic 
approaches and effective therapeutic strategies for patients with AL and HCT recipients. 
The epidemiology of IFI has changed significantly over the last two decades. Candida spp. 
were by far the most common causative fungi more than twenty years ago, however the 
incidence of IMI, particularly IA is increasing.  The apparent change may, in part, be due to 
control of Candida by fluconazole prophylaxis in high risk patients. 
After its peak in 1980’s when Candida spp. became the fourth-commonest cause of 
bloodstream infection in the USA [23], the epidemiology of IC dramatically changed. Before 
the widespread use of antifungal prophylaxis the incidence of IC in HCT recipients was as 
high as 25%, but after the introduction of fluconazole prophylaxis in high risk patients the 
incidence of IC has been steadily decreasing  [24]. This phenomenon is mostly caused by a 
reduction in incidence of C. albicans [25], whereas the incidence of azole resistant Candida 
spp. such as C. glabrata [26] and C. krusei [27] has risen. Analysis of multi-institutional 
surveys from Europe showed that between September 1997 and December 1999 in patients 
with hematological malignancies C. albicans was responsible for only 35% of cases of 
candidemia. The majority of cases were caused by non-albicans Candida spp, predominantly 
C. tropicalis and C. krusei in 24% and 12% of cases respectively [28].  Another retrospective 
study from a single center in Brazil showed that during a 9-year period (from 1995 to 2003) 
non-albicans Candida spp. were responsible for as high as 79% of all candidemia episodes in 
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patients with hematological malignancies [29]. Therefore, despite the fact that azole 
prophylaxis led to a significant reduction in the incidence of IC in high-risk patients, azole-
resistant species such as C. krusei or C. glabrata could be responsible for breakthrough 
infections [30-31]. 
The epidemiology of Aspergillus spp. in the US is also evolving. Similar to the changing 
incidence of Candida infections, it is likely that the prophylactic use of agents with anti-mold 
activity is responsible for a change in epidemiology of IA. Over the last 15 years the 
incidence of IA has tripled in allo-HCT recipients in one large transplant center [32]. If 
earlier epidemiologic data showed that around 90% of all IA cases were caused by A. 
fumigatus [32], the recent multicenter report demonstrated that in HCT recipients the 
proportion of IA caused by A. fumigatus has decreased to 56% with a relative increase in the  
incidence of other Aspergillus spp. including A. flavus, A. terreus, A. niger and A. versicolor 
[33].  
In recent years previously rare molds have been emerging as important pathogens in high 
risk patients. There is a rising incidence of  IFI caused by  Fusarium spp., Rhizopus spp., 
Scedosporium spp., although the absolute numbers of these infections are still relatively low 
[32].  In allo-HCT recipients the incidence of both Fusarium spp. and Rhizopus spp. infections 
doubled in the period 1985–1999 and was accounting for 18 % of all IMI [32]. It was noted 
that in some centers an increase in incidence of Zygomycosis infections occurred after the 
introduction of voriconazole for prophylaxis and treatment of IFI [34]. Although, data from 
25 US transplant centers over a 3-year period showed very low incidence of Zygomycetes 
(less than five cases per 1,000 transplants) with no increased incidence after introduction of 
voriconazole [35]. 
3. Risk factors 
Risk factors for IFIs in patients with leukemia and HCT recipients depend on both causative 
pathogens and host factors. Since the most common fungal pathogens are opportunitistic, 
they capable of causing life-threatening infections almost exclusively in immunosuppressed 
host and the IFI risk directly depends on the duration of neutropenia and severity of 
immunosuppression.  Patients with AL are considered high risk for IFI if prolonged (>7 
days duration) neutropenia (absolute neutrophil count <100 cells/mm3) following cytotoxic 
chemotherapy is anticipated and/or significant medical co-morbid conditions such as 
hypotension, pneumonia, new-onset abdominal pain, or neurologic changes are present. 
The same criteria apply for HCT recipients alongside with additional risk factors, mainly 
graft versus host disease (GVHD) and prolonged immunosuppressive therapy. In ASCT 
recipients significant alterations of humoral and cellular immunity typically resolve within 3 
months, therefore, for such patients the risk for IFI beyond that time is minimal. Immune 
reconstitution happens slower after allo-HCT and usually approaches normality by 1 year if 
GVHD does not develop. The occurrence of chronic GVHD significantly impairs immune 
reconstitution by requiring prolonged and often intensive immunosuppressive therapy. 
These patients remain at a high risk for IFI if chronic GVHD persists and requires 
continuing immunosuppressive therapy.   
Neutropenic patients with AL and HCT recipients are at a risk for IC, particularly in the 
absence of antifungal prophylaxis. The risk of IC in both AL patients and HCT recipients 
also depends on the duration of neutropenia, severity of  mucosal injury, and the presence 
of a central venous catheter [36]. Patients with neutropenia are also at risk for IMI, 
www.intechopen.com
Invasive Fungal Infections in Patients with 
Acute Leukemia and Hematopoietic Stem Cell Transplant Recipients 
 
661 
particularly IA. The underlying disease itself and treatment intensity directly influence the 
risk of AI; patients with AML have the highest risk for IA with an incidence of 
approximately 20 times greater than that among patients with lymphoma and multiple 
myeloma [37]. The precise risk for IA in AML patients varies in different published series, 
however in most studies it ranges between 5 and 10%,  depending on the disease status, 
duration of neutropenia, and the types of anti-neoplastic agents used for a leukemia 
treatment [37-42], where patients undergoing chemotherapy for relapsed or refractory 
leukemia are at greatest risk, whereas patients undergoing an induction chemotherapy for a 
newly diagnosed leukemia are at a lower risk and those, who are receiving consolidation 
therapy are at  lowest risk. In HCT recipients the risk for IA significantly depends on the 
type of transplant (ASCT versus allo-HCT); conditioning regimen (myeloablative, non-
myeloablative, reduced intensity); stem cell graft source (related, unrelated, haploidentical, 
umbilical cord, HLA matched or mismatched, T-cell depleted); post-transplant interventions 
(salvage chemotherapy, prolonged treatment with glucocorticoids and anti-rejection 
medications); and the development of post-transplant complications, particularly GVHD 
[43-45].  Overall risk for IA is low in ASCT represents (1–2%) because there is only a brief 
period of immunosupression and neutropenia in these patients [46].  In allo-HCT recipients, 
the risk for IA is substantially higher with a trimodal incidence distribution [32, 47-48]. The 
first peak occurs during the pre-engraftment period where the main risk factor is prolonged 
neutropenia which is similar to neutropenic patients with leukemia who did not receive 
transplantation. The second peak occurs between 2 to 3 months after the allo-HCT in 
patients with acute GVHD being treated with corticosteroids. The third peak occurs after 
one year post-transplant in patients who continue to require systemic immunosupression 
for extensive chronic GVHD. Late onset (41–180 days) occurrences of IA were more common 
in recipient of mismatched or unrelated donor HCT; in patients who received T-cell 
depleted or CD34-selected stem cell products; in patients receiving corticosteroids; in 
patients with neutropenia, lymphopenia, GVHD, CMV disease; and in patients with 
respiratory virus infections. Other factors such as iron overload and a toll-like receptor 4 
polymorphism are recognized as independent risk factors for IA in HCT recipients [49-50].  
Among less frequent IMI, Zygomycosis tends to develop relatively late, usually after 90 
days post HSCT and is more commonly seen in patients with underlying MDS, chronic 
GVHD and patients receiving treatment of GVHD [32]. Alternatively, severe, but rare 
infections with Scedosporium spp, occurring early, usually in neutropenic AL patients and 
during the pre-engraftment period in HCT recipients [51]. 
4. Diagnostic approaches 
To improve outcomes of high risk patients with AL and HCT transplant recipients it is 
critical to establish the diagnosis of IFI early, but currently there is no single diagnostic 
method that has a sufficient sensitivity and specificity to determine IFI. Therefore, timely 
diagnosis of IFI should be made on the basis of a constellation of clinical signs, confirmatory 
imaging studies and laboratory findings.   
Imaging studies.  
Even minor abnormalities on chest radiographs (CXR) in high risk patients should prompt 
further investigation, which often includes computed tomography (CT) of the chest. When 
suspicion of invasive pulmonary Aspergillosis is high, it is very important to pursue CT 
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scanning of the chest, because CXR may be negative in up to 10% cases of invasive 
pulmonary Aspergillosis, whereas only 3% CT scans are falsely negative [52]. If possible, 
images need to be compared with prior ones to exclude over interpreting persistent 
abnormalities, which are not related to acute infection, such as scarring or other tissue 
changes caused by previous radiation or administration of chemotherapy. The pulmonary 
infiltrates due to IMI are generally nodular.   CT imaging findings that are more specific 
radiologic signs of IA are early on a “halo sign” when the central nodular area of fungal 
invasion is surrounded by a ground-glass appearing hemorrhage and a "crescent sign" may 
occur later as a result of necrosis and cavitation of lung tissue. In a large multicenter study, 
most patients with documented IA had one or more dense nodules and nearly two thirds 
had a halo sign [53]. The chest CT defines the extent of the disease process with a greater 
accuracy than CXR and can also be used repeatedly to monitor the response to therapy. 
Better visualization of lung tissue on CT scan also helps to define optimal sampling sites and 
to select the most appropriate invasive diagnostic procedure, such as with bronchoalveolar 
lavage with or without transbronchial biopsy, image guided needle biopsy, video-assisted 
thoracoscopic or open lung biopsy.  Importantly, during therapy lung infiltrates and clinical 
symptoms may appear or get worse with immune reconstitution and resolution of severe 
neutropenia when an inflammatory response develops at the site of tissue damage by an 
invasive fungal pathogen. It was demonstrated that initiation of therapy directed against 
Aspergillus when a halo sign has been identified resulted in significantly improved survival 
[54-55]. 
Laboratory approaches.  
Candida spp. are often detected in peripheral blood of patients with IC, however, blood 
cultures have a low sensitivity for the diagnosis, being negative in up to 50% of cases with 
autopsy-proven disseminated Candidiasis [56]. Blood cultures can also be positive for a 
variety of other fungal pathogens, but  blood cultures are practically never positive in the 
case of disseminated Aspergillosis or Zygomycosis [7]. 
Aspergillus was isolated from sputum in only 8% to 34%, and from BAL in 45% to 62% of 
patients with invasive Aspergillosis [57].  In case of pulmonary Zygomycosis, it is poorly 
isolated from sputum, with positive cultures <25% and the yield of BAL is not higher [58]. 
Fungal element identification in tissue of the presumed site of infection can be considered as 
a “gold standard” however, possibility of colonization of the respiratory secretions by 
environmental fungi may lead to over diagnosis. Tissue biopsies in the case of visceral 
fungal infections are frequently difficult to obtain due to critical condition of the patient and 
concomitant severe thrombocytopenia. If there is cutaneous involvement, punch biopsy of 
skin lesions are often required to establish the diagnosis. For a suspected fungal infection 
special stains for fungal organisms, such as the Gomori methenamine silver stain, are 
necessary because routine histologic stains may often not be sufficient to visualize the tissue 
invasion by fungi.  
Detection of yeasts or fungal elements (hyphae) in the tissue by microscopic examination 
should be followed by a subsequent culture to identify a specific organism, since 
morphology is not sufficiently specific. Aspergillus is characterized by narrow, septated 
hyphae with acute angle branching and, in comparison with other fungi, it grows relatively 
rapidly with a visible growth within 3 days if inoculum size is adequate. The hyphae of 
Fusarium in tissue resemble those of Aspergillus.  Zygomycetes characteristically are 
pauciseptate, wider, ribbon like in contrast to Aspergillus in tissue.  Positive cultures of tissue 
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of most molds, but especially Zygomycosis is challenging given the difficulty of extracting 
fungal elements from infected tissues [59] 
Because of numerous limitations related to culture techniques, adjunctive non-cultural 
methods such as galactomannan (GM) antigen, b-(1-3)-D glucan (BG) and PCR-based 
methods are now being implemented for a timely diagnosis of IFI, primarily IA, particularly 
when tissue sample is not obtained [60-63]. If PCR-based techniques are still considered 
investigational [63], the clinical value of serum GM and BG assays was confirmed in 
prospective trials. Both tests now are accepted as supplementary diagnostic tests for an early 
detection of common IFI in high risk patients. A positive GM test preceded the development 
of clinical symptoms of IFI in the majority of patients in studies [60]. The BG has high 
sensitivity and specificity with a capability to detect many clinically relevant fungal 
pathogens including Candida spp, Aspergillus spp, Pneumocystis spp, and Fusarium spp, but not 
Zygomycetes spp or Cryptococcus spp. [62, 64]. Its strength is the ability to detect a variety of 
the most common relevant fungal pathogens in AL and HCT patients; its weakness is its 
inability to determine which pathogen is present.  In patients with AML and MDS receiving 
chemotherapy the negative predictive value of BG approached 100%; a single positive test 
and two or more sequentially positive results had the specificity of 90% and > 95% 
respectively [64]. The role of BG assay in HCT recipients has not been well studied [65] and 
requires further investigation.  
The serum GM assay detects Aspergillus and Penicillium spp. (a rare pathogen in AL and 
HCT patients).  GM is a major component of Aspergillus cell walls and released during a 
rapid growth of hyphae. The serum GM assay can identify the presence of fungal growth in 
tissues during invasive infection and often quite early even before the development of any 
clinical signs, radiologic abnormalities or fungal growth in culture. Detection of GM antigen 
by ELISA in the serum has been widely retrospectively and prospectively studied with a 
wide range of reported sensitivities depending on the study population and definitions of 
the test positivity [60, 66-74] . The GM assay had only moderate accuracy in the patients 
with hematologic malignancies with a pooled specificity of 58-70% and sensitivity of 92-
95%, and in HCT recipients a pooled specificity of 65-86%- and sensitivity 65-82% [75]. The 
predictive accuracy of GM is negatively affected by a concomitant use of piperacillin-
tazobactam [76] and amoxicillin-clavulanate [77] due to the presence of GM in the antibiotic 
formulations, and a false positive GM signal may be detected up to 5 days after 
discontinuation of these medications. The use of antifungal prophylaxis with agents having 
anti-mold activity could be associated with  falsely negative GM tests [67]. False positivity of 
GM assay was also described in case of infection with Penicillium spp. [78] and Histoplasma 
capsulatum [79] because these microorganisms share cross reactive antigens.  
GM can also be detected in other body fluids during IA infection involving those fluids or 
adjacent tissues, including urine, CSF and bronchoalveolar lavage (BAL) [80-82]; however, 
clinical utility of the assay obtained from other sources than serum is under clinical 
investigation.  Preliminary data has suggested that detection of GM in BAL fluid [83] could 
be an reliable adjunct test with a specificity and sensitivity exceeding of those in BAL fungal 
culture [84-85] and some studies suggest BAL GM to be more sensitive than serum GM [86] 
PCR assays to detect and identify fungal pathogens are being developed and ongoing 
clinical testing, but not yet available for a commercial use [74]. Although development and 
clinical implementation of PCR assays for fungal species such as Aspergillus spp. holds an 
enormous promise, multiple obstacles, particularly widespread environmental fungal 
contamination and difficulties in DNA extraction, must be overcome before PCR-based 
techniques will be clinically useful [87-89]. 
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5. Treatment and prevention 
There are four common antifungal strategies used in current clinical practice to combat IFI.  
These include antifungal prophylaxis, empirical therapy, pre-emptive (or diagnostics-
driven) therapy and treatment of proven and probable IFI. 
Antifungal prophylaxis 
The goal of antifungal prophylaxis is to prevent IFI with an administration of the antifungal 
agent(s) in high risk patients.  Antifungal prophylaxis is a rapidly evolving field. 
Prophylaxis is considered clinically beneficial when the risk of a life-threatening IFI 
outweighs the risks of toxic effects and drug interactions, and the risk for emergence of drug 
resistance associated with the antifungal agent used. Optimally, antifungal prophylaxis 
should also be cost-effective. Therefore, the choice of empirical antifungal treatment is 
considered based on the prevalence of the most likely fungal pathogens, along with 
considerations about toxicities, resistance, and cost. 
The most widely used agent for IFI prophylaxis in patients with AL and HCT recipients is 
fluconazole, an agent with activity against most (but not all) Candida spp.. Prospective 
studies demonstrated reductions in IFI caused by yeast organisms when fluconazole was 
given prophylactically at the dose of 400 mg daily in allo- HCT and ASCT recipients [90-91]. 
In one trial prophylaxis with fluconazole resulted in a statistically significant reduction of 
IFI to 3% as compared to 16% in the placebo group [90].  Administration of fluconazole up 
to engraftment was able to effectively prevent IFI caused by Candida spp. with the exception 
of C. krusei. Although there was no difference in overall mortality in patients who received 
prophylaxis with fluconazole as compared to those who received placebo, infection related 
mortality was significantly reduced [90]. In another trial [91], patients who received 
fluconazole prophylaxis during the first 75 post-transplant demonstrated a statistically 
significant clinical benefit  with a reduction of IFI  from 18% to 7%, a decrease in infection-
related mortality from 22% to 12%, and improvement of overall mortality from 35% to 20% 
as compared to placebo group [91]. The enduring benefit of fluconazole prophylaxis in HCT 
recipients even beyond the time the drug was given was noted in a follow-up analysis of the 
Slavin study [92]. Based on such benefits fluconazole at a daily dose of 400 mg was widely 
accepted as a standard of care for IFI prophylaxis in high risk HCT recipients, endorsed by 
consensus guidelines [93];  however controversy remains regarding the optimal duration of 
prophylaxis and whether to stop it at the time of engraftment or continue until GVHD 
resolves and its treatment has ceased. It is also not completely clear if patient groups who at 
a lesser risk for a development of IC than recipients of myeloablative HCT, such as patients 
with AL, ASCT and non-ablative transplant recipients derive similar clinical benefit from 
fluconazole prophylaxis.  
Another widely studied agent for antifungal prophylaxis in high risk patients is 
itraconazole, which has activity against Aspergillus spp. in addition to Candida spp. [94]. 
Comparison of itraconazole to fluconazole as a long term prophylactic agent (until day 100 
or 180 post-transplant) in HCT recipients showed no difference in overall survival [95-96]; in 
one of the trials   a reduction in the incidence of IFI in itraconazole arm was noted [95] but 
not in the other [96]. Despite its attractive anti-mold activity, the lack of proven clinical 
advantage over fluconazole [96-98], suboptimal bioavailability [95], higher mortality rate 
[95-96] and a higher incidence of adverse events, particularly more renal and hepatic 
toxicities [96] associated with itraconazole administration make this agent suboptimal for 
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routine prophylaxis of IFI in high risk patients.  In a meta-analysis of itraconazole trials, an 
Aspergillus protective effect was noted in patients given a bioavailable daily dose of at least 
200 mg twice daily (typically seen when itraconazole is given as oral solution at a twice 
daily dose of 200mg per dose [94] .  
Voriconazole is a well-tolerated triazole with an extended-spectrum of activity including 
activity against Aspergillus spp.. A large multicenter, randomized trial compared 
voriconazole with fluconazole for prevention of IFI after myeloablative allo-HCT [99]. In 
that trial patients were randomized to receive antifungal prophylaxis with study drugs for 
100 days or for 180 days if patients were considered high risk. All patients were intensively 
monitored with twice weekly serum GM assays for initial 60 days, then at least weekly until 
day 100. In the case of positive GM or clinical signs suggestive of IFI patients were followed 
with radiographic studies and invasive diagnostic procedures for confirmation of IFI. 
Despite statistically non-significant trends to fewer IFI, particularly IA, and less frequent use 
of empiric antifungal therapy in voriconazole arm, the primary endpoint- fungal-free 
survival (alive and free from proven, probable, or presumptive IFI patients) at 6 months was 
similar in both groups. In addition, there was no difference in incidence of severe adverse 
events, relapse-free and overall survival at 6 months. Thus, prophylaxis with voriconazole 
did not improve 6-month fungal-free and overall survival as compared to fluconazole if 
intensive monitoring and a structured approach for empiric antifungal therapy were used 
[99]. Voriconazole is available in both intravenous and oral formulations, which allows its 
extended use to prolonged periods of high risks for the development of IFI. One of the major 
drawbacks of voriconazole is the lack of activity against Zygomycetes. Although multicenter 
studies with voriconazole [35, 99-100]  showed no increased incidence of IFI caused by 
Zygomycetes in patients received voriconazole prophylaxis,  there are single center 
retrospective case series suggesting an association of voriconazole use with more 
Zygomycoses.  Thus, this issue bears further scrutiny over time.  This is quite difficult 
because of the difficulty in culturing Zygomycetes in tissue. Echinocandins have a potential 
advantage over fluconazole given the broader spectrum of activity, in particular, against 
fluconazole resistant C. krusei or C. glabrata, and the anti-Aspergillus activity, although the 
latter has not yet been proved in clinical trials. A prospective comparison of micafungin to 
fluconazole for antifungal prophylaxis in neutropenic patients undergoing HCT showed 
compatible efficacy, safety profile, overall survival and reduced the need for empiric 
antifungal therapy in patients receiving micafungin [101]. The major disadvantage of 
micafungin use for a fungal prophylaxis is the need for intravenous administration and 
substantially greater cost; however this agent might be preferred over fluconazole in the 
centers with high prevalence of infections caused by non-albicans Candida spp.  
Posaconazole is a triazole with a broad spectrum of activity against both yeasts and molds. 
It is active against pathogens such as the Zygomycetes which are resistant to many widely 
used antifungal agents. Such a broad spectrum of activity makes this agent an attractive 
alternative to fluconazole for prophylaxis of IFI. Posaconazole is approved for prophylaxis 
in neutropenic patients with AML or MDS based on the results of randomized multicenter 
studies where it was shown to be superior to fluconazole or itraconazole in the prevention 
of IFI [102]. In that study prophylactic administration of posaconazole resulted in improved 
overall survival, although at the cost of higher incidence of serious adverse events 
attributable to study drug [102]. Since significant numbers of the patients in the 
posaconazole group were receiving chemotherapy there was a possibility that greater 
toxicity of the posaconazole may have resulted from a harmful interactions with 
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chemotherapy agents. This has not been adequately studied.  In patients with GVHD 
posaconazole was similar to fluconazole in prevention of all types of IFI and, not 
surprisingly given its anti-mold activity, superior in reducing the incidence of IA and 
mortality related to fungal infections as compared to fluconazole [30]. Based on these results 
posaconazole was approved in the US for antifungal prophylaxis in high risks patients, 
however this agent has not been studied in the pre-engraftment phase of HCT.  
Development of extensive chronic GVHD significantly increases the risk of late IFI (more 
than 100 days post-transplant), predominantly IA, with a reported incidence as high as 
almost 40% in one series [103]. Therefore, anti-mold prophylaxis with posaconazole in 
patients with extensive chronic GVHD could be beneficial in these patients.  
Amphotericin B (AmpB) is not currently used for prophylaxis of IFI due to its excessive 
toxicity and infusion-related events. However, recently aerosolized AmpB was 
prospectively tested in patients with AL and allo-HCT recipients and led to reduction in the 
incidence of invasive pulmonary Aspergillosis; however administration of the drug was 
interrupted in a substantial proportion of patients (45%) due to cough during inhalation, 
weakness preventing the use the aerosol delivery system and technical problem with the 
aerosol delivery system. Moreover, aerosol dose and delivery device have not yet been 
determined, therefore further study is necessary before the clinical utility of this agent can 
be determined [104]. 
The risk for IFI is substantially lower in the majority of ASCT recipients as compared to allo-
HCT recipients.  These patients usually do not require routine anti-yeast prophylaxis.  
However, for high risk sub-populations of ASCT recipients such as patients with underlying 
hematological malignancies, history of prolonged neutropenia, significant mucosal damage, 
and treatment within fludarabine or 2-CDA within 6 months prior ASCT ant-yeast 
prophylaxis is recommended [15].  
Empirical treatment  
Empirical treatment is an initiation or modification of an existing antifungal treatment in 
high risk patients with persistent fever of unknown source unresponsive to antibacterial 
agents. Although, approximately one-third of neutropenic patients with cancer receive an 
antifungal drug due to persistent fever, only less than 5% of these patients subsequently 
demonstrate the presence of IFI [102, 105-107]. Therefore, initiation of empirical antifungal 
therapy solely on the basis of persistent fever can be legitimately questioned.   
The most common fungal pathogen in neutropenic patients is Candida.  Anti-yeast prophylaxis 
dramatically reduces the risk for IC.  However, in persistently febrile neutropenic patients not 
given antifungal prophylaxis IMI or fluconazole-resistant Candida infections represent the 
most common threats. Oral, non-absorbable antifungal drugs, such as oral AmpB, nystatin and 
clotrimazole troches are capable of reducing superficial colonization and control local mucosal 
candidiasis, but, surprisingly, do not reduce the risk for IC. 
There is not enough data for recommendations regarding a particular empirical antifungal 
agent for patients who are already receiving anti-mold prophylactic coverage, however 
changing treatment to a different class of intravenous anti-mold agent should be considered, 
given the possibility that breakthroughs of fungal infection could be caused by resistant 
organisms.  Another concern is that breakthrough IFI may be due to inadequately low 
serum levels of voriconazole or posaconazole when these agents administered orally 
because of the variability of blood levels after HCT [108-109].  
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For more than 30 years AmpB has been used for an empirical antifungal treatment, but with 
development of newer agents, its therapeutic role in the current management of fungal 
infections is minimal, due to excessive toxicity, particularly nephrotoxicity and infusion-
related events. Alternative  formulations of AmpB such as liposomal AmpB, AmpB colloidal 
dispersion, AmpB lipid complex; azoles with anti-mold activity such as itraconazole or 
voriconazole, and caspofungin are widely used because of better tolerability and reduced 
systemic toxicity, however there are no data that have demonstrated their superior efficacy 
to AmpB [105, 107, 110-112].  
Voriconazole is recognized by many experts as a suitable alternative to a liposomal AmpB 
as an empirical antifungal therapy in patients with neutropenia and persistent fever [106] 
and currently widely used for an empirical therapy for high risk patients, particularly for an 
empirical treatment of probable IMI.   
Pre-emptive therapy  
The need for  empirical antifungal therapy in febrile high risk patients have been questioned 
because of the very low percentage of such fevers that are actually due to IFI [42].  The 
advances in our ability for early detection of fungal infections have ushered in a new 
strategy, pre-emptive therapy.  Pre-emptive treatment refers to therapy of highly suspected 
IFI supported by the presence of clinical symptoms, radiological findings and/or adjunctive 
laboratory tests [54-55, 113].  
The feasibility of preemptive antifungal therapy in high risk patients with the use of serial 
GM testing and early CT scans was prospectively evaluated in 131 neutropenic episodes.  
All patients were given fluconazole prophylaxis to eliminate Candida as a possible cause of 
persistent fever.  Forty one of 117 episodes (35%) met the criteria for empirical therapy 
persistent or recurrent fevers [55]. Use of preemptive approach in such patients was 
associated with a 78% reduction (from 35% to 8%) of antifungal therapy without a 
compromise in identifying (and treating) IFI.  Indeed, early detection allowed for initiation 
of antifungal therapy earlier with the pre-emptive strategy.  The clinical utility of 
preemptive antifungal therapy was also evaluated in a prospective study, which included 
patients with AML receiving induction or consolidation therapy,  ASCT recipients and in 
other patients with prolonged neutropenia, however, allo-HCT recipients were excluded 
[114]. In that study, clinical symptoms, chest CT findings indicative of IFI, documented 
Aspergillus colonization or a positive GM were used to initiate a preemptive therapy with 
either AmpB or liposomal AmpB, depending on renal function.  Although there was no 
difference in overall mortality, probable or proven IFI were more commonly detected in 
preemptive treatment arm than in the empirical treatment one (13/143 vs. 4/150). An 
increase in IFI was seen only in the subset of patients who did not receive antifungal 
prophylaxis and the increase was due to an increased incidence of IC [114].  This 
emphasizes the need for anti-Candida prophylaxis, if the screening testing is designed 
primarily for detecting Aspergillus. 
In another study PCR-based preemptive antifungal therapy was compared with an 
empirical treatment with liposomal amphotericin B in patients after allo-HCT [113]. PCR-
based approach led to an increased use of anti-fungal therapy and reduced 30-day mortality, 
but there was no difference in the incidence of IFI or 100-day survival. 
These observations suggest that some of high risk neutropenic patients with persistent fever 
may not need an automatic empirical antifungal therapy if they receiving anti-yeast 
prophylaxis and closely monitored under certain specific conditions [114-117]. However, if 
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laboratory, clinical or radiologic abnormality suggestive of probable fungal infection is 
identified, prompt initiation with of antifungal therapy with an agent that includes anti-
mold activity is needed.  
Despite being an attractive alternative, the preemptive approach is currently regarded as 
investigational by many and not widely accepted although its use is embraced and its 
promise is discussed in consensus guidelines [118] 
Treatment of established IFI 
Early recognition and treatment of invasive fungal infections in AL and HCT recipients are 
important clinical challenges. Early initiation is a key to optimizing treatment outcomes for 
both Candida and Aspergillus [119-121]. The European Organization for Research and 
Treatment of Cancer/Mycoses Study Group (EORTC-MSG) has proposed criteria to define 
proven or probable IFI [122]. New antifungal agents offer choices that in some cases are less 
toxic than older drugs and in other cases are more efficacious. Novel strategies that combine 
the new diagnostic tools with new drugs, are being evaluated to change our approaches to 
these deadly infections [123] 
Treatment of IC. 
Candidemia is associated with a high mortality, especially in patients with delayed 
treatment, therefore antifungal therapy in patients with IC should be started as soon as 
possible [119]. If a central venous catheter(s) is in place and suspected to be causative for IC, 
it should be removed.  Although AmpB was historically the preferred therapy with excellent 
activity against most Candida spp., lipid amphotericin formulations were just as effective 
with less toxicity.  Other agents are also effective treatment options.  Multiple studies, 
conducted mostly in non-neutropenic patients and patients with solid malignances, 
demonstrated a high efficacy of fluconazole in patients with candidemia  [119]. In patients 
with IC fluconazole was found to be  non-inferior and significantly better tolerated then 
AmpB [119] IC, but less effective than anidulafungin IC [124]. Although well tolerated, there 
are gaps in its spectrum of activity with C. krusei being intrinsically resistant and many 
strains of C. glabrata requiring higher fluconazaole concentrations for inhibition and some 
strains being outright resistant.  Despite the fact that anidulafungin was mainly studied in 
non-neutropenic patients, better efficacy [124] and emergence of fluconazole-resistant 
Candida spp. such as C. krusei or C. glabrata [125-126] make the echinocandins preferable 
choices for the initial treatment of IC in patients with AL and HCT recipients.  After the 
confirmation of susceptibility of Candida spp. to fluconazole clinically stable patients without 
prior azole exposure can be stitched to fluconazole. Initial preferred dose of fluconazole is 
800 mg a day with a subsequent reduction to 400 mg a day in clinically stable patients with 
resolved neutropenia [127]. In a large randomized study caspofungin showed compatible 
efficacy and significantly better side effects profile in comparison to AmpB in neutropenic 
patients with candidemia [128]. Given its good safety profile and efficacy against non-
albicans Candida spp. caspofungin is indicated in severely ill, clinically unstable neutropenic 
patients or patients with hepatosplenic Candidasis [129] 
Treatment of IMI 
Voriconazole is the preferred initial agent for the treatment of IA [130] . It is effective and 
well tolerated both as primary and salvage treatment [131]. A large randomized study 
showed a higher response and survival rate with fewer Aspergillus-related deaths and side 
effects with voriconazole compared to AmpB for primary therapy of IA [115]. 
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Although there is a very limited data regarding posaconazole activity as a first line agent in 
the treatment of IA as an initial agent of choice, substantial evidence supports its activity in 
the salvage setting after a failure of or intolerance to other antifungal treatments [132]. There 
are few data regarding clinical role of caspofungin as a first-line treatment for IA, but it is 
effective with a response up to 50% as a salvage agent in patients with IA who failed or 
intolerant to standard antifungal therapy [133]. The role of micafungin or anidulafungin for 
the treatment of IA has not been well studied but are active as salvage therapy.  
Efficacy and safety of AmpB lipid complex (ABLC) as first-line or second-line therapy was 
demonstrated in large numbers of patients with hematologic malignancy or HCT recipients 
[134]. Another study showed that one third of allo-HCT recipients with IA responded to 
ABLC, with a response of 41% and 21% when ABCL used as a first line treatment and in 
patients with GVHD respectively [135].  In both studies administration of ABLC had only 
minimal effects on renal function in the majority of patients.  Liposomal AmpB also has been 
shown to be effective as salvage therapy with fewer infusion related and renal toxicities.   
Two doses of liposomal AmpB were evaluated (10mg/day versus 3 mg/day) to determine 
the optimal dose for initial therapy.  Both doses had comparable response rates but the 10 
mg/day dose was associated with more renal toxicity [136] 
The treatment options for Zygomycosis are more limited and less well studied.  Patients 
with Zygomycosis showed a good response to high doses of liposomal AmpB (dose at least 
5 mg/kg) [59] or ABLC [137]. In the case of CNS or sinus involvement additional surgical 
resection of necrotic tissue in patients with Zygomycosis significantly appears to be 
associated with improved survival as compared to antifungal therapy alone [137-138]. 
Posaconazole is an effective agent with response rates of about 50–80% when uses as a 
salvage treatment in patients with Zygomycosis [139-140]. 
Therapeutic Drug Monitoring 
Therapeutic drug monitoring has not been found to be useful for the polyene and 
echinocandin classes of antifungal drugs.  However, the oral formulations of the extended 
spectrum triazoles have been found to have variability in blood concentrations and multiple 
drug interactions.  Multiple studies have explored whether these variations have clinical 
consequences in terms of efficacy. Itraconazole oral formulations have been seen to have 
variable bioavailability in multiple studies [141-145]. Higher doses appear to have greater 
antrifungal effects in both animals and humans [141, 145-148] .  Voriconazole , when taken 
orally also has been shown to havevariable bioavailability, especially in HCT recipients [149-
151].Voriconazole is metabolized in the liver via the cytochrome P450 dependent 
mechanism, predominantly by CYP2C19 isoenzyme which exhibits genetic polymorphism 
resulting in reduced drug metabolism in 15–20% patients of Asian descent, and 3–5% of 
Caucasians and Blacks [150]. Low voriconazole levels have been have been reported in 
patients with documented breakthrough infections, whereas super therapeutic levels may 
lead to hepatotoxicity and encephalopathy [150-151].  Less information is known about 
posaconazole, but it too has been shown to have variable bioavailability [152-156].   There is 
some suggestion that low levels may be associated with lower effectiveness [156-157]. 
Controversy remains regarding the use of routine monitoring of azole drug levels, however 
most experts agree that measurement of levels should be performed in patients with 
documented breakthrough infection or infections not responding to oral triazole therapy. A 
change to, or addition of, different class antifungal agent is recommended until the 
determination of the drug blood level. If drug level is found to be sub-therapeutic, resuming 
the drug at a higher dose should be considered.  
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Combination antifungal therapy 
Combination antifungal therapy may theoretically lead to better efficacy with shorter 
courses of therapy, reduced toxicity and emergence of resistance. However potential 
drawbacks of combination therapy might  include potential  antagonistic effects of the 
antifungal drugs used in combination, potential increase in toxicity, and greater cost may 
offset the potential value of this approach [158]. A randomized trial demonstrated that in 
non-neutropenic patients with candidemia due to species other than C. krusei combination 
therapy with fluconazole and AmpB resulted in a faster clearance of fungi from the 
bloodstream as compared to fluconazole alone [159].  Based on this result combination of 
fluconazole and AmpB could be recommended as an option for the treatment of IC [160], 
however the data regarding combination antifungal therapy for candidemia in neutropenic 
patients with leukemia and HCT recipients is lacking. Small retrospective studies showed 
better responses to the combination of caspofungin plus liposomal AmpB for primary IA 
infection [161] or for refractory pneumonia [162]. Another small retrospective study 
compared the voriconazole plus caspofungin combination to a single-agent voriconazole. In 
this study an improved 3-month survival in HCT recipients or patients receiving 
chemotherapy with IA who had failed primary therapy with the combination, but there was 
no difference in survival at 1 year [163].   Thus currently there is no data supporting a 
benefit of combination therapy in patients with IA.  
6. Conclusion 
Over the past two decades, significant progress has been made in the prophylaxis, diagnosis 
and treatment of IFI in patients with AL and HCT recipients. Introduction of newer 
antifungal agents, better supportive care and more effective diagnostic tools resulted to a 
considerable improvement of clinical outcomes for such high risk patients. However, 
despite advances in prevention and management of systemic fungal infections, IFI remain a 
significant clinical problem for AL patients and HCT recipients. Further progress should be 
made towards improvements in diagnostic techniques, development of novel antifungal 
drugs and introduction of immunotherapy approaches for high risk patients. Future efforts 
should also be focused on better understanding of fungal immunobiology and 
implementation of personalized therapy based on  immunologic, metabolic and genetic 
profiles of high risk patients.  
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